Free-text search
Articles per year:
Content Types
-
Anocca doses first Swedish patient with its TCR-T therapy
Five patients have so far been treated with Anocca’s in-house developed TCR-T cell therapy candidate for pancreatic cancer, with the latest becoming the first patient in Sweden. The Södertälje-based company is also reporting early signs of biological activity in the Phase I trial.
-
Sanofi strikes another multibillion-dollar deal – four candidates in focus
Sanofi and Regeneron are stepping up their long-standing partnership. The companies are now investing in four new antibody drugs in a deal that could be worth up to $8 billion.
-
Study finds key gut bacterium undetectable in one in three Swedish infants
One in three Swedish infants have no detectable levels of a bacterium that helps support the developing immune system, according to a new Swedish study. The figure is notably high compared with similar studies from the UK and US.
-
Danish biosolutions company expands U.S. factory
Novonesis has expanded its facility in the U.S. cheese capital.
-
Invisible hearing implant launched – entire device sits beneath the skin
A cochlear implant in which all components, including the microphone, are implanted beneath the skin is now being launched across Europe. According to Ingeborg Hochmair, CEO and co-founder of MED-EL, the idea has been nearly 50 years in the making.
-
Swedish biotech AnaCardio raises €62.5m to advance heart failure drug
Swedish biotech company AnaCardio has raised €62.5 million, equivalent to more than SEK 700 million, in its largest funding round to date. “It’s a big day for us,” says Patrik Strömberg, the company’s CEO.
-
Anna Törner: Time for new body ideals?
Why are perfectly healthy people turning to high-tech medicines to achieve outdated beauty ideals? Anna Törner asks in her latest column.
-
Kodiak shares more than double after positive eye drug results
A successful Phase III trial in age-related macular degeneration sent shares in US-based Kodiak Sciences soaring on Monday.
-
Egetis lands FDA approval: “Biggest milestone in the company’s history”
Swedish Egetis Therapeutics has secured FDA approval for its rare disease drug Emcitate, clearing the way for a US launch within weeks. “We are transitioning from a late-stage development biotech company into a commercial company,” CEO Nicklas Westerholm tells Life Science Focus.
-
Swedish Alzheimer’s project wins 19 million dollar US research grant
An Alzheimer’s research project led by associate professor Sebastian Palmqvist at Lund University has been awarded 19.4 million dollars in US research funding. The aim is to develop a new FDA-approved blood test for the disease within five years.
-
Multicancer blood test moves closer to FDA approval
A blood test designed to detect signals from more than 50 types of cancer before symptoms appear could be on its way to FDA approval, after an advisory panel of experts issued a favourable recommendation.
-
Elfcare to integrate health data with ChatGPT – leaves sharing to users
Healthcare company Elfcare has launched a new connector that allows users to share results from its health assessments with AI assistants. Speaking to Life Science Focus’s sister publication Medtech Magazine, co-founder Julia Elf discusses the initiative and how the company approaches questions around data protection and responsibility.
-
Danish BioInnovation Institute sets sights on Europe
Great science is not enough to build successful companies. As BioInnovation Institute looks beyond Denmark, CEO Jens Nielsen sees access to the right capital as one of the biggest obstacles facing Europe’s research-based startups.
-
Novartis makes a move in red‑hot radiopharma space
Novartis is expanding its radiopharmaceutical pipeline through a licensing agreement with Chinese BoomRay Therapeutics worth up to 900 million dollars.
-
Sweden takes half of Nordic spots among world’s top healthtech companies
Ten Nordic companies have made it onto TIME’s list of the World’s Top HealthTech Companies 2026, and half of them are Swedish. Denmark accounts for three, while Norway and Iceland each have one company on the list.
-
Disruptive sells former Guard platform – deal ‘not financially material’
What was formerly Guard Therapeutics became Disruptive Pharma following a reverse acquisition. Now, one of the remaining parts of the former Guard business is being sold as the listed company shifts its full focus to Disruptive’s formulation technology.
-
TLV on Kisunla: High cost, high uncertainty
High treatment costs and considerable uncertainty regarding the durability of the treatment effect. That is TLV’s overall verdict on Eli Lilly’s Alzheimer therapy Kisunla.
-
Changing jobs in the Nordics? Avoid this common mistake
It is easy to assume that working in Copenhagen, Stockholm, Oslo or Helsinki will not be all that different from working in a neighbouring Nordic country. According to career coach Tina Persson, that assumption is one of the biggest pitfalls.
-
FDA clears 3.95 million dollar gene therapy
For the first time, there is now an approved gene therapy for Sanfilippo syndrome type A. The disease is extremely rare, and the treatment is among the most expensive in the world — with a list price of nearly four million dollars.
-
Novartis expands brain‑delivery push with Sironax deal
Novartis continues to invest in new methods for the efficient delivery of medicines to the brain.
-
A new name for a broader outlook
Life science is, by its very nature, an international industry. Companies, research and people move across borders – and anyone covering the sector needs to do the same.
-
Stem cell setback in infant heart condition
U.S.-based Longeveron plans to implement cost‑saving measures and “explore strategic options” after a Phase II trial failed to meet its primary endpoint in a rare congenital heart condition in infants.
-
Rarity Bioscience targets hidden disease signal with new test
Rarity Bioscience has a lot going on. The Uppsala-based company is launching an ultra-sensitive blood test for systemic mastocytosis while preparing to move into premises more than twice the size at Uppsala Business Park.
-
David Lang on the future of robotic surgery: More people should gain access
David Lang, Head of the Nordic Region at robotic surgery company Intuitive, delivers the opening address at Medtechdagen 2026 next week. On stage, he will discuss the field’s development and how the technology can benefit more patients.
BREAKING